<p>瑞士银行集团在最近向证券交易委员会提交的 13F 表格中披露，第四季度将其在 Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON - 免费报告）的股份减少了 42.5%。该公司在季度内出售了 93,687 股后，持有 126,674 股 Eton 的股票。截至最近一次向证券交易委员会的提交，瑞士银行集团持有 Eton Pharmaceuticals 0.47% 的股份，价值 2,142,000 美元。</p>
<p>获取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家机构投资者和对冲基金最近也增持或减持了在 ETON 的股份。Millennium Management LLC 在第一季度将其在 Eton Pharmaceuticals 的持股增加了 156.3%。Millennium Management LLC 现在拥有 355,929 股该公司的股票，价值 4,620,000 美元，此前在此期间又购买了 217,042 股。高盛集团在第一季度将其在 Eton Pharmaceuticals 的持股增加了 34.9%。高盛集团现在拥有 175,220 股该公司的股票，价值 2,274,000 美元，此前在此期间又购买了 45,341 股。Jane Street Group LLC 在第一季度将其在 Eton Pharmaceuticals 的持股增加了 49.1%。Jane Street Group LLC 现在拥有 95,919 股该公司的股票，价值 1,245,000 美元，此前在此期间又购买了 31,596 股。摩根大通在第二季度将其在 Eton Pharmaceuticals 的持股增加了 114.5%。摩根大通现在拥有 242,580 股该公司的股票，价值 3,457,000 美元，此前在此期间又购买了 129,467 股。最后，Legal &amp; General Group Plc 在第二季度以约 41,000 美元的价格获得了 Eton Pharmaceuticals 的新头寸。目前，27.86% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部交易活动</h2>
<p>在 Eton Pharmaceuticals 的其他消息中，内部人士 David Krempa 于 5 月 27 日星期三出售了 19,679 股该公司的股票。股票以平均价格 31.47 美元出售，总价值为 619,298.13 美元。出售后，内部人士持有 25,249 股该公司的股票，价值 794,586.03 美元。这代表了他们持股的 43.80% 的减少。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。内部人士在上个季度共出售了价值 3,229,921 美元的 100,000 股公司股票。16.49% 的股票由公司内部人士持有。</p>
<h2>分析师评级调整</h2>
<p>几位研究分析师对 ETON 股票发表了看法。Craig Hallum 在 3 月 20 日的研究报告中将 Eton Pharmaceuticals 的目标价格从 30.00 美元上调至 35.00 美元，并给予该股票 &#34;买入&#34; 评级。B. Riley Financial 在 3 月 20 日的研究报告中将 Eton Pharmaceuticals 的目标价格从 26.00 美元上调至 31.00 美元，并给予该股票 &#34;买入&#34; 评级。HC Wainwright 在 5 月 15 日的研究报告中将 Eton Pharmaceuticals 的目标价格从 52.00 美元上调至 57.00 美元，并给予该股票 &#34;买入&#34; 评级。Wall Street Zen 在 3 月 21 日的研究报告中将 Eton Pharmaceuticals 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。最后，Zacks Research 在 4 月 17 日的报告中将 Eton Pharmaceuticals 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。三位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Eton Pharmaceuticals 目前的共识评级为 &#34;持有&#34;，平均目标价格为 41.00 美元。</p>
<p><strong>阅读我们关于 ETON 的最新报告</strong></p>
<h2>Eton Pharmaceuticals 股票上涨 3.5%</h2>
<p>NASDAQ ETON 的股票在周四开盘时为 32.40 美元。Eton Pharmaceuticals, Inc. 的 12 个月低点为 13.09 美元，12 个月高点为 35.66 美元。该公司的市值为 8.8744 亿美元，市盈率为 -462.79，贝塔值为 0.82。该公司的债务与股本比率为 0.62，流动比率为 1.21，速动比率为 0.88。该公司的 50 日移动平均线为 26.59 美元，200 日移动平均线为 20.03 美元。</p>
<p>Eton Pharmaceuticals（纳斯达克：ETON - 获取免费报告）最近在 5 月 14 日星期四公布了季度财报。该公司报告每股收益（EPS）为 0.05 美元，低于共识预期的 0.10 美元（差额为 0.05 美元）。Eton Pharmaceuticals 的净利润率为 -1.70%，股本回报率为 -5.68%。该业务在季度内的收入为 2427 万美元，而分析师的预期为 2231 万美元。股票分析师预计 Eton Pharmaceuticals, Inc. 在当前财政年度将发布 0.82 的每股收益。</p>
<h2>Eton Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Eton Pharmaceuticals, Inc. 是一家专注于开发、生产和商业化针对罕见和被忽视疾病的仿制药和专有药物的专业制药公司。公司总部位于佛罗里达州西棕榈滩，利用其在激素疗法和复杂分子方面的专业知识，解决患者需求高、竞争有限的治疗领域。自 2016 年成立以来，Eton 一直致力于建立一个多元化的产品组合，将成熟的仿制药与针对性品牌产品相结合。</p>
<p>该公司的产品线包括甲状腺激素替代药物，如干燥甲状腺和利奥甲状腺素，以及用于弓形虫病的吡美莫司片。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Eton Pharmaceuticals</li>
<li>Abercrombie 在强劲的第一季度财报后反弹，延续胜利之势</li>
<li>TeraWulf 投资于电力基础设施以引领人工智能建设</li>
<li>亚马逊的 Alexa 购物功能加强了已经强劲的牛市论点</li>
<li>Keysight：人工智能和国防股票看到大幅目标价格提升</li>
</ul>
<p><strong>想知道其他对 ETON 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eton Pharmaceuticals, Inc. (NASDAQ:ETON - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Eton Pharmaceuticals 吗？</h2>
<p>在考虑 Eton Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eton Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eton Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ETON

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

<p>瑞士银行集团在第四季度将其在 Eton Pharmaceuticals, Inc.的持股减少了 42.5%，目前持有 126,674 股，价值 214 万美元。其他机构投资者，包括千禧管理公司和高盛，增加了他们的持股。内部人士 David Krempa 出售了 19,679 股，减少了 43.80% 的持股比例。分析师对 ETON 的评级意见不一，普遍评级为 “持有”，平均目标价为 41.00 美元。Eton 的股票开盘价为 32.40 美元，市值为 8.8744 亿美元</p>

<p>UBS Group AG reduced its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 42.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 126,674 shares of the company's stock after selling 93,687 shares during the quarter. UBS Group AG owned 0.47% of Eton Pharmaceuticals worth $2,142,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>瑞士银行集团在最近向证券交易委员会提交的 13F 表格中披露，第四季度将其在 Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON - 免费报告）的股份减少了 42.5%。该公司在季度内出售了 93,687 股后，持有 126,674 股 Eton 的股票。截至最近一次向证券交易委员会的提交，瑞士银行集团持有 Eton Pharmaceuticals 0.47% 的股份，价值 2,142,000 美元。</p>
</div><p>Get <strong>Eton Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in ETON. Millennium Management LLC grew its position in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after buying an additional 217,042 shares during the period. Goldman Sachs Group Inc. grew its position in Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company's stock worth $2,274,000 after buying an additional 45,341 shares during the period. Jane Street Group LLC grew its position in Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company's stock worth $1,245,000 after buying an additional 31,596 shares during the period. JPMorgan Chase &amp; Co. grew its position in Eton Pharmaceuticals by 114.5% during the second quarter. JPMorgan Chase &amp; Co. now owns 242,580 shares of the company's stock worth $3,457,000 after buying an additional 129,467 shares during the period. Finally, Legal &amp; General Group Plc acquired a new position in Eton Pharmaceuticals during the second quarter worth about $41,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也增持或减持了在 ETON 的股份。Millennium Management LLC 在第一季度将其在 Eton Pharmaceuticals 的持股增加了 156.3%。Millennium Management LLC 现在拥有 355,929 股该公司的股票，价值 4,620,000 美元，此前在此期间又购买了 217,042 股。高盛集团在第一季度将其在 Eton Pharmaceuticals 的持股增加了 34.9%。高盛集团现在拥有 175,220 股该公司的股票，价值 2,274,000 美元，此前在此期间又购买了 45,341 股。Jane Street Group LLC 在第一季度将其在 Eton Pharmaceuticals 的持股增加了 49.1%。Jane Street Group LLC 现在拥有 95,919 股该公司的股票，价值 1,245,000 美元，此前在此期间又购买了 31,596 股。摩根大通在第二季度将其在 Eton Pharmaceuticals 的持股增加了 114.5%。摩根大通现在拥有 242,580 股该公司的股票，价值 3,457,000 美元，此前在此期间又购买了 129,467 股。最后，Legal &amp; General Group Plc 在第二季度以约 41,000 美元的价格获得了 Eton Pharmaceuticals 的新头寸。目前，27.86% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of the company's stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the sale, the insider owned 25,249 shares of the company's stock, valued at $794,586.03. This represents a 43.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 100,000 shares of company stock valued at $3,229,921 over the last quarter. 16.49% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Eton Pharmaceuticals 的其他消息中，内部人士 David Krempa 于 5 月 27 日星期三出售了 19,679 股该公司的股票。股票以平均价格 31.47 美元出售，总价值为 619,298.13 美元。出售后，内部人士持有 25,249 股该公司的股票，价值 794,586.03 美元。这代表了他们持股的 43.80% 的减少。该出售在向证券交易委员会提交的文件中披露，该文件可通过 SEC 网站访问。内部人士在上个季度共出售了价值 3,229,921 美元的 100,000 股公司股票。16.49% 的股票由公司内部人士持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several research analysts have weighed in on ETON shares. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. B. Riley Financial upped their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. HC Wainwright upped their target price on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 21st. Finally, Zacks Research downgraded shares of Eton Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, April 17th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and an average target price of $41.00.</p>
<div class="lb-trans"><p>几位研究分析师对 ETON 股票发表了看法。Craig Hallum 在 3 月 20 日的研究报告中将 Eton Pharmaceuticals 的目标价格从 30.00 美元上调至 35.00 美元，并给予该股票 &#34;买入&#34; 评级。B. Riley Financial 在 3 月 20 日的研究报告中将 Eton Pharmaceuticals 的目标价格从 26.00 美元上调至 31.00 美元，并给予该股票 &#34;买入&#34; 评级。HC Wainwright 在 5 月 15 日的研究报告中将 Eton Pharmaceuticals 的目标价格从 52.00 美元上调至 57.00 美元，并给予该股票 &#34;买入&#34; 评级。Wall Street Zen 在 3 月 21 日的研究报告中将 Eton Pharmaceuticals 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。最后，Zacks Research 在 4 月 17 日的报告中将 Eton Pharmaceuticals 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。三位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Eton Pharmaceuticals 目前的共识评级为 &#34;持有&#34;，平均目标价格为 41.00 美元。</p>
</div><p><strong>Read Our Latest Report on ETON</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ETON 的最新报告</strong></p>
</div><h2>Eton Pharmaceuticals Stock Up 3.5%</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 股票上涨 3.5%</h2>
</div><p>Shares of NASDAQ ETON opened at $32.40 on Thursday. Eton Pharmaceuticals, Inc. has a 12-month low of $13.09 and a 12-month high of $35.66. The company has a market capitalization of $887.44 million, a PE ratio of -462.79 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The firm's 50-day moving average is $26.59 and its two-hundred day moving average is $20.03.</p>
<div class="lb-trans"><p>NASDAQ ETON 的股票在周四开盘时为 32.40 美元。Eton Pharmaceuticals, Inc. 的 12 个月低点为 13.09 美元，12 个月高点为 35.66 美元。该公司的市值为 8.8744 亿美元，市盈率为 -462.79，贝塔值为 0.82。该公司的债务与股本比率为 0.62，流动比率为 1.21，速动比率为 0.88。该公司的 50 日移动平均线为 26.59 美元，200 日移动平均线为 20.03 美元。</p>
</div><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million during the quarter, compared to analysts' expectations of $22.31 million. Equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（纳斯达克：ETON - 获取免费报告）最近在 5 月 14 日星期四公布了季度财报。该公司报告每股收益（EPS）为 0.05 美元，低于共识预期的 0.10 美元（差额为 0.05 美元）。Eton Pharmaceuticals 的净利润率为 -1.70%，股本回报率为 -5.68%。该业务在季度内的收入为 2427 万美元，而分析师的预期为 2231 万美元。股票分析师预计 Eton Pharmaceuticals, Inc. 在当前财政年度将发布 0.82 的每股收益。</p>
</div><h2>Eton Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc. 是一家专注于开发、生产和商业化针对罕见和被忽视疾病的仿制药和专有药物的专业制药公司。公司总部位于佛罗里达州西棕榈滩，利用其在激素疗法和复杂分子方面的专业知识，解决患者需求高、竞争有限的治疗领域。自 2016 年成立以来，Eton 一直致力于建立一个多元化的产品组合，将成熟的仿制药与针对性品牌产品相结合。</p>
</div><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p>
<div class="lb-trans"><p>该公司的产品线包括甲状腺激素替代药物，如干燥甲状腺和利奥甲状腺素，以及用于弓形虫病的吡美莫司片。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eton Pharmaceuticals</li>
<li>Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak</li>
<li>TeraWulf Bets on Power Infrastructure to Lead AI Build-Out</li>
<li>Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case</li>
<li>Keysight: The AI and Defense Stock Seeing Big Price Target Boosts</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Eton Pharmaceuticals</li>
<li>Abercrombie 在强劲的第一季度财报后反弹，延续胜利之势</li>
<li>TeraWulf 投资于电力基础设施以引领人工智能建设</li>
<li>亚马逊的 Alexa 购物功能加强了已经强劲的牛市论点</li>
<li>Keysight：人工智能和国防股票看到大幅目标价格提升</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ETON?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 ETON 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eton Pharmaceuticals, Inc. (NASDAQ:ETON - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ETON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eton Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eton Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eton Pharmaceuticals 并不在名单上。</p>
</div><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eton Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG

Market Beat

Eton Pharmaceuticals

瑞银集团

高盛

摩根大通

Legal & General Group Plc

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

瑞银集团出售了 Eton Pharmaceuticals, Inc. $ETON 的股票